

2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable)
 Amendment One (1) 08/07/2015

6. ISSUED BY CODE 7. ADMINISTERED BY (If other than Item 6) CODE
 National Cancer Institute
 Office of Acquisitions, TSB
 Riverside Five, Suite 400
 8490 Progress Drive, Room 4036
 Frederick, MD 21701-4998

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
 All potential offerors.

9A. AMENDMENT OF SOLICITATION NO.
 RFP N02CO54416-02
 9B. DATED (SEE ITEM 11)

10A. MODIFICATION OF CONTRACT/ORDER NO.
 10B. DATED (SEE ITEM 13)

CODE FACILITY CODE

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended.
 Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
 (a) By completing items 8 and 15, and returning 1 copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment your desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)
 Responses to Questions Received

E. IMPORTANT: Contractor is not, is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
 The purpose of this modification is to provide responses to questions received on 8/5/15 in reference to RFP No. N02CO54416-02.

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
 Mandie S. White, Contracting Officer, NCI

15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED
 (Signature of person authorized to sign) (Signature of Contracting Officer) 8/7/15

RFQ Number: N02CO54416-02, Full and Open Competition

Amendment No. One (1)

National Institutes of Health (NIH), National Cancer Institute (NCI)

Office of Acquisitions (OA), Treatment and Support Branch (TSB)

Date of Issuance: August 7, 2015

The above numbered Request for Quotation (RFQ) is amended as set forth below. The hour and date specified for receipt of responses remains unchanged.

This Amendment #1 provides responses to questions received on 8/5/15, as stated below.

Inquiry 1 -

Question 1: It looks like [this requirement] would be for a center to be the one to process the tissue.

Response 1: The primary activity of the TSS is to recruit patients and collect biospecimens and clinical data. Besides minimal sample preparation at the time of collection, biospecimen processing will be conducted at the BCR.

Inquiry 2 -

Question 1: Should a formal submission be submitted or should we go through the list of tumors and give you what we can accrue?

Response 1: You should submit a formal proposal under the appropriate RFQ. This solicitation is for a direct agreement with the NCI.

Question 2: The RFQ does not list an end date; alternatively, is there an "n" per tumor type to be collected and the end date?

Response 2: The final closing date of the subject RFQ is 12/17/15 at 3pm EPT. The goal for each tumor type is 200 qualified cases.

Question 3: The RFQ also does not provide any details related to qualifications other than no treatment. The stage and grade obviously will have tremendous impact; like we discovered with ovaries. Also awareness of standard of care. An example from the past is the radioactive seed localization that is standard of care now for breast excisions; disqualified all our breast CA cases.

In that vein, most lung cancers that are "collectable" are higher stage get neoadjuvant therapy. We had pointed this out to caHUB. Is there a workaround? One way would be to get needle cores during diagnostic EBUS; however 300 mg is a lot of tissue via this approach. All of the above will impact the number of cases we can provide.

Response 3: Currently, there is no work-around when standard of care includes neoadjuvant therapy. Sites should project how many cases they expect to accrue that will meet the criteria listed in the RFQ.

Question 4: We already have a payment schedule that Leidos had provided for the different pieces of work.

Response 4: This NCI RFQ is not associated with Leidos and will have its own payment schedule.

Inquiry 3 –

Question 1: [Our organization] is a designated small business, so should we go only for the RFQ N02CO54417-02 (Total 100% Small Business Set-Aside) or should we also participate in the N02CO54416-02 (Full and Open Competition).

Response 1: If your organization is a small business, then you should be proposing only under the small business set-aside RFQ No. N0CO54417-02.

END OF AMENDMENT #1.